Financial Performance & Growth - Global medical cannabis net revenue reached $64.8 million in Q1, a 37% increase compared to the prior year period[17] - Aurora achieved positive free cash flow of $9.2 million in Q1 FY26, representing 42% year-over-year growth[111] - The company achieved positive adjusted EBITDA of $10.8 million in Q1 FY26, a 209% increase year-over-year[111] - Bevo contributed record revenues of approximately $23.9 million in Q1, up 4% compared to the prior year period[99] Market Leadership & Expansion - International medical revenue increased 85% in Q1 FY 2026 compared to the prior year period[9] - Aurora is the 1 Canadian Medical share by revenue, with net revenue increasing by 2% compared to the prior year period[9] - Aurora Europe was the 2 supplier of medical cannabis to each core market of Germany and Poland in Q1 FY26[35] - MedReleaf Australia, an Aurora subsidiary, holds approximately 16% market share by revenue and pharmacy dispensed volumes in Australia[57] Product Innovation & Strategy - Innovations in genetics result in all-in per unit costs that are at least 30% better than legacy cultivars[12] - Farm Gas became the 1 selling cultivar in Poland shortly after its launch, with THC levels around 27%[22, 36]

As filed with the Securities and Exchange Commission on [ ], 2023. Registration No. 333- (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KINDLY MD, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (I.R.S. Employer Identification No.) 5097 South 900 East Suite 100 Salt Lake City, UT 84117 (38 ...